Am J Perinatol 2024; 41(03): 241-247
DOI: 10.1055/s-0043-1775974
SMFM Fellowship Series Article

Statewide Implementation of Universal Third-Trimester Repeat HIV Testing in Illinois

Lynn M. Yee
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
2   24/7 Illinois Perinatal HIV Hotline, Chicago, Illinois
,
Laurie D. Ayala
2   24/7 Illinois Perinatal HIV Hotline, Chicago, Illinois
,
Alexis M. Roach
3   Mother and Child Alliance (MACA), Chicago, Illinois
,
Anne Statton
3   Mother and Child Alliance (MACA), Chicago, Illinois
,
Sukhdeep Randhawa
3   Mother and Child Alliance (MACA), Chicago, Illinois
,
Patricia M. Garcia
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
2   24/7 Illinois Perinatal HIV Hotline, Chicago, Illinois
,
Emily S. Miller
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
2   24/7 Illinois Perinatal HIV Hotline, Chicago, Illinois
3   Mother and Child Alliance (MACA), Chicago, Illinois
4   Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, The Warren Alpert Medical School, Brown University, Providence, Rhode Island
› Institutsangaben
Funding None.

Abstract

Objective This article aims to assess statewide uptake of HIV repeat testing in the first 2 years after the implementation of an amendment to the Illinois Perinatal HIV Prevention Act (IPHPA) mandating universal repeat HIV testing in the third trimester.

Study Design This is a retrospective, population-based study of all birthing individuals in Illinois (2018–2019). Data were collected using the state-mandated closed system of perinatal HIV test reporting. We evaluated the incidence of mother–infant pairs with negative early tests and repeat third-trimester tests (RTTTs) performed in adherence with the law, as well as the timing of the performance of the RTTTs (outpatient vs. inpatient). Chi-square tests of trend by quarter were performed to ascertain sustainability.

Results Of 138,805 individuals delivered in 2018, 80.6% presented with early test and RTTTs. In 2018, outpatient RTTTs improved from 71.8% (quarter 1) to 85.1% (quarter 4; p < 0.001). In 2018, the proportion of mother–infant dyads who received testing that was adherent to the IPHPA Amendment was 92.1, 95.5, 96.7, and 96.4% in quarters 1 through 4, respectively (p < 0.001). In 2019, outpatient RTTTs performance remained high (87.4%) and stable (p = 0.06). In 2019, 99.9% of mother–infant dyads had testing adherent to the mandate in quarters 1 through 4 (p = 0.39). Of individuals who presented without RTTTs, 93.5% (2018) and 98.8% (2019) underwent inpatient testing before delivery.

Conclusion Implementation of RTTTs in Illinois was rapid, successful, and sustained in its first 2 years. Public health methodologies from Illinois may benefit other states implementing RTTT programs.

Key Points

  • In 2018, Illinois enacted statewide RTTT for HIV among all parturients.

  • In 2019, over 99% of mother–infant dyads had documentation of both early and repeat HIV testing before hospital discharge.

  • Implementation of repeat third-trimester HIV testing in Illinois was rapid, successful, and sustained in its first 2 years.

  • Public health methodologies from Illinois may benefit other states implementing similar programs.

Note

A portion of these data were presented as a poster presentation at the 2020 Society of Maternal-Fetal Medicine 40th Annual Meeting in Grapevine, Texas.


Supplementary Material



Publikationsverlauf

Eingereicht: 05. Dezember 2022

Angenommen: 10. September 2023

Artikel online veröffentlicht:
18. Oktober 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. Accessed December 30, 2021 at: https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines
  • 2 Centers for Disease Control and Prevention Division of HIV/AIDS Prevention. Pregnant Women, Infants and Children: Elimination of Mother-to-Child HIV Transmission (EMCT) in the United States. Centers for Disease Control and Prevention. Accessed February 22, 2017 at: https://www.cdc.gov/hiv/group/gender/pregnantwomen/emct.html
  • 3 Sperling RS, Shapiro DE, Coombs RW. et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335 (22) 1621-1629
  • 4 Cooper ER, Charurat M, Mofenson L. et al; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29 (05) 484-494
  • 5 Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22 (08) 973-981
  • 6 Chou R, Cantor AG, Zakher B, Bougatsos C. Screening for HIV in pregnant women: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. Ann Intern Med 2012; 157 (10) 719-728
  • 7 American College of Obstetricians and Gynecologists Committee on Obstetric Practice and HIV Expert Work Group. Prenatal and perinatal Human Immunodeficiency Virus Testing: Expanded Recommendations, Committee Opinion Number 635. Obstet Gynecol 2015; 125: 1544-1547
  • 8 Moyer VA. U.S. Preventive Services Task Force*. Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2013; 159 (01) 51-60
  • 9 Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64 (RR-03): 1-137
  • 10 Nesheim S, Taylor A, Lampe MA. et al. A framework for elimination of perinatal transmission of HIV in the United States. Pediatrics 2012; 130 (04) 738-744
  • 11 Mahy M, Stover J, Kiragu K. et al. What will it take to achieve virtual elimination of mother-to-child transmission of HIV? An assessment of current progress and future needs. Sex Transm Infect 2010; 86 (Suppl. 02) ii48-ii55
  • 12 Whitmore SK, Taylor AW, Espinoza L, Shouse RL, Lampe MA, Nesheim S. Correlates of mother-to-child transmission of HIV in the United States and Puerto Rico. Pediatrics 2012; 129 (01) e74-e81
  • 13 Read JS, Cohen RA, Hance LF. et al; NISDI Perinatal/LILAC Study Group. Missed opportunities for prevention of mother-to-child transmission of HIV-1 in the NISDI Perinatal and LILAC cohorts. Int J Gynaecol Obstet 2012; 119 (01) 70-75
  • 14 Liao C, Golden WC, Anderson JR, Coleman JS. Missed opportunities for repeat HIV testing in pregnancy: implications for elimination of mother-to-child transmission in the United States. AIDS Patient Care STDS 2017; 31 (01) 20-26
  • 15 Frange P, Chaix ML, Veber F, Blanche S. Missed opportunities for HIV testing in pregnant women and children living in France. Pediatr Infect Dis J 2014; 33 (02) e60-e62
  • 16 Cassimatis IR, Ayala LD, Miller ES, Garcia PM, Jao J, Yee LM. Third-trimester repeat HIV testing: it is time we make it universal. Am J Obstet Gynecol 2021; 225 (05) 494-499
  • 17 American College of Obstetricans and Gynecologists. ACOG Committee Opinion No. 752: prenatal and perinatal human immunodeficiency virus testing. Obstet Gynecol 2018; 132 (03) e138-e142
  • 18 Lu L, Legwaila K, Motswere C, Smit M, Jimbo W, Creek T. HIV incidence in pregnancy and the first post-partum year and implications for PMTCT programs. Francistown, Botswana: 2008: 2009
  • 19 Garcia PM, Kalish LA, Pitt J. et al; Women and Infants Transmission Study Group. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341 (06) 394-402
  • 20 Singh SLM, Surendera BSR, Borkowf CB, Nesheim SR. HIV seroconversion during pregnancy and mother-to-child HIV transmission: data from the enhanced perinatal surveillance projects, United States, 2005–2010. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2013 ; Atlanta, GA: March 3-6
  • 21 Peters H, Thorne C, Tookey PA, Byrne L. National audit of perinatal HIV infections in the UK, 2006-2013: what lessons can be learnt?. HIV Med 2018; 19 (04) 280-289
  • 22 Wong AE, Garcia PM, Olszewski Y. et al. Perinatal HIV testing and diagnosis in Illinois after implementation of the Perinatal Rapid Testing Initiative. Am J Obstet Gynecol 2012; 207 (05) 401.e1-401.e6
  • 23 Yee LM, Miller ES, Statton A. et al. Sustainability of statewide rapid HIV testing in labor and delivery. AIDS Behav 2018; 22 (02) 538-544
  • 24 AIDSVu. AIDS Vu Local Data. Accessed November 1, 2021 at: Chicago. https://aidsvu.org/state/illinois/chicago/
  • 25 AIDSVu. AIDS Vu Local Data: Illinois. https://aidsvu.org/local-data/united-states/midwest/illinois/
  • 26 Ayala LDME, Carter SD, Yee LM, Son M, Statton A, Garcia PM. Repeat third trimester HIV testing: An opportunity to prevent maternal to child transmission. Paper presented at: American Public Health Association 143rd Annual Meeting and Expo, 2015; Chicago, IL; October 31 - November 4
  • 27 State of Illinois. Illinois Perinatal HIV Prevention Act. P.A. 93-566, amended by PA 94-0910 (2006), amended by P.L. 95-702 (2007), amended by P.A. 100-265. In: Illinois So, ed. P.A. 93-566, amended by PA 94-0910 (2006), amended by P.L. 95-702 (2007), amended by O.A. 100-265 (2017)2003; 2017
  • 28 Mother & Child Alliance. Mother & Child Alliance. Accessed November 1, 2021 at: https://motherandchildalliance.org/
  • 29 AIDS Foundation of Chicago. The Illinois Perinatal HIV Prevention Law and 2006 Amendment. 2006 www.aidschicago.org/resources/legacy/pdf/2006/adv_perinatal_factsheet.pdf
  • 30 FIMR/HIV Prevention Methodology National Resource Center. FIMR/HIV Prevention Methodology National Resource Center Overview and Manual of Operations. 2015 http://www.fimrhiv.org/documents/2015_FIMRHIV_Manual_of_Operations.pdf
  • 31 Szlachta-McGinn A, Aserlind A, Duthely L. et al. HIV screening during pregnancy in a U.S. HIV Epicenter. Infect Dis Obstet Gynecol 2020; 2020: 8196342
  • 32 Williams B, Costello M, McHugh E. et al. Repeat antenatal HIV testing in the third trimester: a study of feasibility and maternal uptake rates. HIV Med 2014; 15 (06) 362-366
  • 33 Rogers AJ, Akama E, Weke E. et al. Implementation of repeat HIV testing during pregnancy in southwestern Kenya: progress and missed opportunities. J Int AIDS Soc 2017; 20 (04) e25036
  • 34 Rogers AJ, Weke E, Kwena Z. et al. Implementation of repeat HIV testing during pregnancy in Kenya: a qualitative study. BMC Pregnancy Childbirth 2016; 16 (01) 151
  • 35 Clement AC, Fay KE, Yee LM. Disparities in state-mandated third-trimester testing for syphilis. Am J Obstet Gynecol MFM 2022; 4 (03) 100595